BNT116 is an investigational mRNA-based vaccine developed by BioNTech targeting six tumor-associated antigens frequently expressed in NSCLC.
Exciting news for the RET community! BioNTech’s BNT116 mRNA cancer vaccine trial (NCT05142189) has opened a new RET cohort in advanced NSCLC, enabling combination treatment with RET inhibitors at select U.S. sites. This expansion was championed by Dr. John Heymach (MDACC) who worked closely with the company to broaden the study to include patients with RET alterations.
BNT116 is an investigational mRNA-based vaccine developed by BioNTech targeting six tumor-associated antigens frequently expressed in NSCLC.
The RET cohort will be available at select sites in the United States, including MDACC. Find info of MDACC trial here.
Efficacy data:
Preliminary results from the Phase I LuCa-MERIT-1 trial, presented at AACR 2024, included a 20-patient NSCLC cohort treated with BioNTech’s BNT116 vaccine plus docetaxel and demonstrated a manageable safety profile. Seven patients (35%) achieved a partial response and 10 (50%) had stable disease, resulting in a 35% objective response rate and 85% disease control rate, alongside robust immune activation; updated safety, efficacy, and biomarker data are expected soon.
Another cohort of the BioNTech’s BNT116 vaccine study was also testing the vaccine in combination with cemiplimab (PD-1 inhibitor) in NSCLC who had progressed on prior PD-1 therapy. Find this study here. Among 20 patients, the confirmed objective response rate was 45%, the disease control rate was 80%, and median progression-free survival was 9.9 months. The study advanced to phase 2 (NCT05557591).
Find the clinical trial here.
